4-(chloromethyl)-5-methyl-2-(3,4-dimethylphenyl)oxazole | 932728-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(chloromethyl)-5-methyl-2-(3,4-dimethylphenyl)oxazole
• 英文别名: 4-chloromethyl-2-(3,4-dimethylphenyl)-5-methyloxazol；4-(Chloromethyl)-2-(3,4-dimethylphenyl)-5-methyloxazole；4-(chloromethyl)-2-(3,4-dimethylphenyl)-5-methyl-1,3-oxazole
• CAS: 932728-59-1
• 化学式: C₁₃H₁₄ClNO
• 分子量: 235.713
• InChiKey: XEOXZJSFDPGANE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)-5-methyl-2-(3,4-dimethylphenyl)oxazole 在 4-二甲氨基吡啶 、 1-羟基苯并三唑一水物 、 potassium hydroxide 、 N,N'-二异丙基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 N-(3-(cis-3,5-dimethylpiperidin-1-yl)propyl)-1-((2-(3,4-dimethylphenyl)-5-methyloxazol-4-yl)methyl)piperidine-4-carboxamide
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561
• 作为产物：
  描述：

  3,4-二甲基苯甲醛 在 盐酸 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 溶剂黄146 、 1,2-二氯乙烷 为溶剂， 反应 16.5h， 生成 4-(chloromethyl)-5-methyl-2-(3,4-dimethylphenyl)oxazole
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561

文献信息

• Synthesis and Structure–Activity Relationships of Novel Zwitterionic Compounds as Peroxisome Proliferator Activated Receptor α/γ Dual Agonists with Improved Physicochemical Properties
  作者：Yoshihiro Shibata、Katsuji Kagechika、Mitsuhiro Yamaguchi、Kenji Yoshikawa、Kiyoshi Chiba、Hiromichi Takano、Chiyuki Akiyama、Mayumi Ono、Mina Nishi、Hideo Kubo、Yoshimasa Kobayashi、Hiroyuki Usui

  DOI：10.1248/cpb.c13-00513

  日期：——

  We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitterionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound

  我们在本文中描述了新型两性离子化合物作为基于非噻唑烷二酮（TZD）的过氧化物酶体增殖物激活受体（PPAR）α/γ双激动剂的设计，合成和构效关系（SAR）。在以前的报告中，我们获得了在db / db小鼠中显示出有效PPARα/γ双重激动活性以及极大的降糖作用的化合物1。但是，该化合物具有致命问题，例如有效的细胞色素P450（CYP）3A4直接抑制活性。因此，我们进行了药物优化以改善它们，同时保持有效的PPAR激动活性。结果，通过将呋喃环改变为低亲脂性的1,3,4-恶二唑环得以解决。另外，
• WO2007/37010
  申请人：——

  公开号：——

  公开（公告）日：——